Maxcyte (MXCT) Asset Writedowns and Impairment (2023 - 2026)

Maxcyte has reported Asset Writedowns and Impairment over the past 3 years, most recently at $6000.0 for Q4 2025.

  • Quarterly Asset Writedowns and Impairment changed N/A to $6000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $35000.0 through Dec 2025, up 126.92% year-over-year, with the annual reading at $35000.0 for FY2025, 126.92% up from the prior year.
  • Asset Writedowns and Impairment was $6000.0 for Q4 2025 at Maxcyte, up from -$136000.0 in the prior quarter.
  • Over five years, Asset Writedowns and Impairment peaked at $130000.0 in Q1 2024 and troughed at -$260000.0 in Q2 2024.
  • The 3-year median for Asset Writedowns and Impairment is -$1500.0 (2023), against an average of -$19250.0.
  • The largest YoY upside for Asset Writedowns and Impairment was 138.46% in 2025 against a maximum downside of 50.0% in 2025.
  • A 3-year view of Asset Writedowns and Impairment shows it stood at -$50000.0 in 2023, then crashed by 420.0% to -$260000.0 in 2024, then surged by 102.31% to $6000.0 in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Asset Writedowns and Impairment are $6000.0 (Q4 2025), -$136000.0 (Q3 2025), and $100000.0 (Q2 2025).